By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Dream Foundation Announces Troy Cox, Genentech (RHHBY) Senior Vice President And Officer, Has Been Appointed To The Board Of Directors 6/17/2015 8:57:25 AM
Almac Discovery Wrangles R&D Deal Worth $363.5 Million+ From Genentech (RHHBY) 6/15/2015 6:31:19 AM
EXCLUSIVE: Genentech (RHHBY) Enrolling Patients in Phase III Actemra Trial, Company Tells BioSpace (DHX) 6/10/2015 12:25:59 PM
Genentech (RHHBY) Wins Breakthrough Nod From FDA for Systemic Sclerosis Treatment 6/10/2015 6:14:25 AM
Former Genentech (RHHBY) CFO Launches Digital Lyra Health to Fix Mental Health System 6/5/2015 6:30:55 AM
ASCO15 EXCLUSIVE: Cancer Drug Could Be Next New Melanoma Med Approved by FDA, Says Genentech (RHHBY) Exec 6/1/2015 12:04:23 PM
ASCO15 EXCLUSIVE: Genentech (RHHBY) VP Tells BioSpace (DHX) Gazyva a "Clear Advance" For NHL Treatment 6/1/2015 11:42:30 AM
Genentech (RHHBY)’s Perjeta Regimen Helped People With HER2-Positive Early Breast Cancer Live Longer Without Their Disease Returning Or Getting Worse Compared To Herceptin And Chemotherapy 6/1/2015 11:24:31 AM
Genentech (RHHBY)’s Gazyva Extended The Time People With Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening 6/1/2015 9:44:57 AM
Updated Data Showed Genentech (RHHBY)’s Investigational Combination Of Cobimetinib And Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live For A Year Without Their Disease Worsening 6/1/2015 9:40:10 AM